DOI: 10.1055/s-00034925

Hämostaseologie

LinksSchließen

Referenz

Vlaar APJ, de Bruin S, Busch M. et al.
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.

Lancet Rheumatol 2020;
2 (12) e764-e773

Bibliographische Angaben herunterladen

Aufrufen in: